Effects of alirocumab on types of myocardial infarction : Insights from the ODYSSEY OUTCOMES trial
White, Harvey D. (Auckland City Hospital)
Gabriel Steg, P. (Royal Brompton Hospital (Londres))
Szarek, Michael (SUNY Downstate Medical Center School of Public Health)
Bhatt, Deepak L (Harvard Medical School)
Bittner, Vera A. (University of Alabama at Birmingham)
Diaz, Rafael (Instituto Cardiovascular de Rosario)
Edelberg, Jay M. (Sanofi)
Erglis, Andrejs (University of Latvia)
Goodman, Shaun G. (University of Toronto)
Hanotin, Corinne (Sanofi)
Harrington, Robert A. (Department of Medicine)
Wouter Jukema, J. (Leiden University Medical Center)
Lopes, Renato D. (Duke Clinical Research Institute)
Mahaffey, Kenneth W. (Stanford University School of Medicine)
Moryusef, Angele (Sanofi)
Pordy, Robert (Regeneron Pharmaceuticals)
Roe, Matthew T. (Duke Clinical Research Institute)
Sritara, Piyamitr (Mahidol University)
Tricoci, Pierluigi (CSL Behring)
Zeiher, Andreas Michael (Goethe University)
Schwartz, Gregory G. (University of Colorado School of Medicine)
Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge)
García-Dorado, David (Hospital Universitari Vall d'Hebron)
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau)
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya))
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin-kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1. 8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results Median follow-up was 2. 8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65. 8%) were adjudicated as Type 1, 386 (20. 8%) as Type 2, and 244 (13. 1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0. 85, 95% confidence interval (CI) 0. 77-0. 95; P = 0. 003], with reductions in both Type 1 (HR 0. 87, 95% CI 0. 77-0. 99; P = 0. 032) and Type 2 (0. 77, 0. 61-0. 97; P = 0. 025), but not Type 4 MI.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Alirocumab ; MI types ; Mortality ; Prevention
Published in:	European heart journal, Vol. 40 Núm. 33 (january 2019) , p. 2801-2809, ISSN 1522-9645

DOI: 10.1093/eurheartj/ehz299
PMID: 31121022

9 p, 627.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles